Acelyrin (NASDAQ:SLRN) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Acelyrin (NASDAQ:SLRN) announced its quarterly earnings data on Tuesday. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.08), Yahoo Finance reports. During the same period last year, the business posted ($0.56) EPS.

Acelyrin Price Performance

Shares of SLRN stock opened at $4.18 on Thursday. Acelyrin has a one year low of $3.36 and a one year high of $29.88. The stock has a market cap of $413.95 million, a P/E ratio of -1.71 and a beta of 2.35. The company has a fifty day moving average price of $5.11 and a two-hundred day moving average price of $5.87.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Piper Sandler cut their target price on Acelyrin from $68.00 to $20.00 and set an “overweight” rating for the company in a research report on Wednesday. Wells Fargo & Company upgraded shares of Acelyrin from an “equal weight” rating to an “overweight” rating and set a $13.00 price objective on the stock in a report on Monday, July 8th. Finally, HC Wainwright lowered shares of Acelyrin from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $18.00 to $6.00 in a report on Wednesday. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.